646 related articles for article (PubMed ID: 18342306)
1. In vivo neurochemical effects of the NR2B selective NMDA receptor antagonist CR 3394 in 6-hydroxydopamine lesioned rats.
Sarre S; Lanza M; Makovec F; Artusi R; Caselli G; Michotte Y
Eur J Pharmacol; 2008 Apr; 584(2-3):297-305. PubMed ID: 18342306
[TBL] [Abstract][Full Text] [Related]
2. MK-801 alters the effects of priming with L-DOPA on dopamine D1 receptor-induced changes in neuropeptide mRNA levels in the rat striatal output neurons.
Van De Witte SV; Groenewegen HJ; Voorn P
Synapse; 2002 Jan; 43(1):1-11. PubMed ID: 11746728
[TBL] [Abstract][Full Text] [Related]
3. NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats.
El Arfani A; Bentea E; Aourz N; Ampe B; De Deurwaerdère P; Van Eeckhaut A; Massie A; Sarre S; Smolders I; Michotte Y
Neuropharmacology; 2014 Oct; 85():198-205. PubMed ID: 24863042
[TBL] [Abstract][Full Text] [Related]
4. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys.
Blanchet PJ; Konitsiotis S; Whittemore ER; Zhou ZL; Woodward RM; Chase TN
J Pharmacol Exp Ther; 1999 Sep; 290(3):1034-40. PubMed ID: 10454475
[TBL] [Abstract][Full Text] [Related]
5. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
Pérez V; Sosti V; Rubio A; Barbanoj M; Rodríguez-Alvarez J; Kulisevsky J
Eur J Pharmacol; 2007 Dec; 576(1-3):83-90. PubMed ID: 17888901
[TBL] [Abstract][Full Text] [Related]
6. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
[TBL] [Abstract][Full Text] [Related]
7. Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease.
Löschmann PA; De Groote C; Smith L; Wüllner U; Fischer G; Kemp JA; Jenner P; Klockgether T
Exp Neurol; 2004 May; 187(1):86-93. PubMed ID: 15081591
[TBL] [Abstract][Full Text] [Related]
8. Behavioural effects of a selective NMDA NR1A/2B receptor antagonist in rats with unilateral 6-OHDA+parafascicular lesions.
Truong L; Allbutt HN; Coster MJ; Kassiou M; Henderson JM
Brain Res Bull; 2009 Feb; 78(2-3):91-6. PubMed ID: 19007866
[TBL] [Abstract][Full Text] [Related]
9. Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat.
Nash JE; Brotchie JM
Mov Disord; 2002 May; 17(3):455-66. PubMed ID: 12112191
[TBL] [Abstract][Full Text] [Related]
10. Functional in vitro characterization of CR 3394: a novel voltage dependent N-methyl-D-aspartate (NMDA) receptor antagonist.
Losi G; Lanza M; Makovec F; Artusi R; Caselli G; Puia G
Neuropharmacology; 2006 Mar; 50(3):277-85. PubMed ID: 16236334
[TBL] [Abstract][Full Text] [Related]
11. The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats.
Mela F; Millan MJ; Brocco M; Morari M
Neuropharmacology; 2010 Feb; 58(2):528-36. PubMed ID: 19733554
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of behavioural effects of a selective NMDA NR1A/2B receptor antagonist in the unilateral 6-OHDA lesion rat model.
Warraich ST; Allbutt HN; Billing R; Radford J; Coster MJ; Kassiou M; Henderson JM
Brain Res Bull; 2009 Feb; 78(2-3):85-90. PubMed ID: 18822357
[TBL] [Abstract][Full Text] [Related]
13. The alpha(2) adrenoceptor antagonist idazoxan alleviates L-DOPA-induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopamine-lesioned rats.
Buck K; Voehringer P; Ferger B
J Neurochem; 2010 Jan; 112(2):444-52. PubMed ID: 19895663
[TBL] [Abstract][Full Text] [Related]
14. Striatal dopaminergic fiber recovery after acute L-DOPA treatment in 6-hydroxydopamine (6-OHDA) lesioned rats.
Fang C; Yin J; Xu Z; Wang Y; Xu H; Zhou H; Gao C
Cell Biochem Biophys; 2011 Jan; 59(1):49-56. PubMed ID: 20714825
[TBL] [Abstract][Full Text] [Related]
15. The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.
Nash JE; Ravenscroft P; McGuire S; Crossman AR; Menniti FS; Brotchie JM
Exp Neurol; 2004 Aug; 188(2):471-9. PubMed ID: 15246846
[TBL] [Abstract][Full Text] [Related]
16. MK801 suppresses the L-DOPA-induced increase of glutamate in striatum of hemi-Parkinson rats.
Jonkers N; Sarre S; Ebinger G; Michotte Y
Brain Res; 2002 Feb; 926(1-2):149-55. PubMed ID: 11814417
[TBL] [Abstract][Full Text] [Related]
17. The antiparkinsonian drug budipine stimulates the activity of aromatic L-amino acid decarboxylase and enhances L-DOPA-induced dopamine release in rat substantia nigra.
Biggs CS; Fisher A; Starr MS
Synapse; 1998 Nov; 30(3):309-17. PubMed ID: 9776134
[TBL] [Abstract][Full Text] [Related]
18. Striatal adenosine A(2A) receptor blockade increases extracellular dopamine release following l-DOPA administration in intact and dopamine-denervated rats.
Gołembiowska K; Dziubina A
Neuropharmacology; 2004 Sep; 47(3):414-26. PubMed ID: 15275831
[TBL] [Abstract][Full Text] [Related]
19. MK801 influences L-DOPA-induced dopamine release in intact and hemi-parkinson rats.
Jonkers N; Sarre S; Ebinger G; Michotte Y
Eur J Pharmacol; 2000 Nov; 407(3):281-91. PubMed ID: 11068024
[TBL] [Abstract][Full Text] [Related]
20. The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats.
Rose S; Ramsay Croft N; Jenner P
Brain Res; 2007 Feb; 1133(1):110-4. PubMed ID: 17196564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]